Document 2799
 DOCN  M94A2799
 TI    Clinical studies of xenogeneic HIV-1 immunoglobulin.
 DT    9412
 AU    Osther KB; Fralick R; Hung CH; Thorn RM; Verigen Inc., Hopkinton, MA.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):222 (abstract no. PB0318). Unique
       Identifier : AIDSLINE ICA10/94369776
 AB    An intravenously formulated immunoglobulin G (IgG) derived from HIV-1
       lysate immunized pigs has been used to treat 16 HIV-1 infected patients
       with AIDS signs ranging from asymptomatic to severe. All patients with
       AIDS signs have shown improvement for 2 to 3 months in at least one
       clinical sign. Placebo controlled, blinded trials are ongoing. Two
       patients have received two cycles and one patient three. There has been
       no adverse clinical signs associated with retreatment nor have porcine
       IgG antibodies developed. In patients with p24 antigen, the treatment
       results in immediate and sustained (2-3 mo) clearance. CD4 cell counts
       are usually unchanged over a 3-6 month period, although some patients
       show increases for 2-3 months. In the 3 cycle treated patient, clinical
       signs improved and CD4 counts increased for 2-3 months after each
       treatment cycle. The accumulating evidence suggests that this
       hyperimmune IgG is tolerated on repeated administration; and that it can
       have significant clinical, viral, and immunological effects.
 DE    Animal  Double-Blind Method  Human  HIV Antibodies/*THERAPEUTIC USE  HIV
       Core Protein p24/BLOOD  HIV Infections/*THERAPY  HIV-1/*IMMUNOLOGY
       IgG/*THERAPEUTIC USE  *Immunization, Passive  Leukocyte Count
       Swine/IMMUNOLOGY  Treatment Outcome  T4 Lymphocytes  CLINICAL TRIAL
       MEETING ABSTRACT  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).